Janux Therapeutics, INC Schedule 13G passive stakes

Janus Henderson Group Ltd. has updated its Schedule 13G filing to report a 0.3% beneficial ownership stake in Janux Therapeutics, Inc., indicating no change in control or significant strategic involvement.

Janus Henderson Group plc has reported a beneficial ownership of 6.9% in Janux Therapeutics, Inc., holding 4,196,409 shares as of March 31, 2026.

State Street Corporation has reported a beneficial ownership of 4.1% in Janux Therapeutics Inc. as of March 31, 2026.

FMR LLC has reported beneficial ownership of 4.2% of Janux Therapeutics Inc.'s common stock as of March 31, 2026.

Point72 Asset Management, L.P., along with affiliated entities and Steven A. Cohen, has reported beneficial ownership of 5.0% of Janux Therapeutics, Inc. common stock as of April 28, 2026.

Point72 Asset Management, L.P., along with affiliated entities and Steven A. Cohen, has reported beneficial ownership of 5.0% of Janux Therapeutics, Inc. common stock as of April 28, 2026.

State Street Corporation has reported a 6.4% beneficial ownership stake in Janux Therapeutics Inc. common stock as of December 31, 2025.

Prosight Management LP and its affiliates have reported a collective beneficial ownership of 5.3% in Janux Therapeutics, Inc. common stock.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 5.8% beneficial ownership stake in Janux Therapeutics Inc. common stock as of December 31, 2025.

Janus Henderson Group plc has increased its beneficial ownership in Janux Therapeutics, Inc. to 10% of common stock, holding 6,033,949 shares.

Paradigm BioCapital Advisors LP and related entities reported a 4.9% beneficial ownership stake in Janux Therapeutics, Inc. common stock.

Janus Henderson Group PLC has increased its beneficial ownership in Janux Therapeutics, Inc. to 7.5% of common stock, as disclosed in an amended Schedule 13G filing.

Adage Capital Management and its principals have reported a reduction in their beneficial ownership of Janux Therapeutics, Inc. common stock to 4.27%.

BlackRock, Inc. has filed a Schedule 13G, disclosing a 5.7% beneficial ownership stake in Janux Therapeutics, Inc.'s Common Stock.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 7.7% beneficial ownership stake in JANUX Therapeutics, Inc. common stock.

Paradigm BioCapital Advisors LP, its general partner, and related entities, including Senai Asefaw, M.D., have reported a 6.0% beneficial ownership stake in Janux Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed a Schedule 13G, reporting a passive beneficial ownership of 6.1% of the common stock of JANUX THERAPEUTICS, INC.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has disclosed a passive beneficial ownership of 5.31% in Janux Therapeutics, Inc., totaling 3,061,750 shares of common stock.